Neuphoria Therapeutics Inc
NEUP
Company Profile
Business description
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
Contact
100 Summit Dr
BurlingtonMA01803
USAT: +1 781 439-5551
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
24
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.20 | 9.50 | 0.11% |
| CAC 40 | 7,847.94 | 25.89 | -0.33% |
| DAX 40 | 23,587.37 | 51.19 | -0.22% |
| Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
| FTSE 100 | 8,606.15 | 3.23 | 0.04% |
| HKSE | 23,640.65 | 532.38 | 2.30% |
| NASDAQ | 19,010.09 | 301.74 | 1.61% |
| Nikkei 225 | 38,128.13 | 55.13 | -0.14% |
| NZX 50 Index | 12,779.26 | 7.48 | -0.06% |
| S&P 500 | 5,886.55 | 42.36 | 0.72% |
| S&P/ASX 200 | 8,279.60 | 10.60 | 0.13% |
| SSE Composite Index | 3,403.95 | 29.08 | 0.86% |